Related Experiment Video
Updated: Jun 11, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Current and future management options for myelodysplastic syndromes
Jeffrey Bryan1, Elias Jabbour, Hillary Prescott
1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Drugs
|July 10, 2010
Summary
Recent advancements in myelodysplastic syndromes (MDS) include improved classification and new FDA-approved agents like lenalidomide, enabling tailored patient therapies beyond supportive care.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Myelodysplastic syndromes (MDS) management is complex due to intricate disease biology.
- Historically, supportive care (transfusions, growth factors) was the standard for MDS treatment.
- Recent progress offers new therapeutic avenues for MDS patients.
Purpose of the Study:
- To review current supportive care modalities for myelodysplastic syndromes.
- To discuss US FDA-approved agents for MDS treatment.
- To explore future directions and investigational agents in MDS therapy.
Main Methods:
- Literature review of advancements in MDS classification and treatment.
- Analysis of approved agents including lenalidomide, azacitidine, and decitabine.
- Discussion of ongoing clinical trials for combination therapies in MDS.
Main Results:
- Improved classification systems and prognostic models enhance MDS management.
- Emergence of targeted therapies (lenalidomide, azacitidine, decitabine) offers new treatment options.
- Patient-tailored therapy for specific MDS subgroups is now feasible.
Conclusions:
- Current MDS treatment integrates supportive care with targeted, approved agents.
- Ongoing research focuses on novel combination regimens and investigational therapies.
- Future MDS management will likely involve personalized treatment strategies based on disease subgroups.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:22Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...